These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32961480)

  • 1. Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors.
    Chen Z; Chen H; Zhang Z; Ding P; Yan X; Li Y; Zhang S; Gu Q; Zhou H; Xu J
    Eur J Med Chem; 2020 Nov; 206():112793. PubMed ID: 32961480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of tissue selective liver X receptor agonists for the treatment of atherosclerosis without causing hepatic lipogenesis.
    Li C; Chen H; Chen X; Li Y; Hua P; Wei J; Song C; Gu Q; Zhou H; Zhang J; Xu J
    Eur J Med Chem; 2019 Nov; 182():111647. PubMed ID: 31499362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of new LXRβ agonists as glioblastoma inhibitors.
    Chen H; Chen Z; Zhang Z; Li Y; Zhang S; Jiang F; Wei J; Ding P; Zhou H; Gu Q; Xu J
    Eur J Med Chem; 2020 May; 194():112240. PubMed ID: 32248003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Tetrachlorophthalimides as Liver X Receptor β (LXRβ)-Selective Agonists.
    Nomura S; Endo-Umeda K; Makishima M; Hashimoto Y; Ishikawa M
    ChemMedChem; 2016 Oct; 11(20):2347-2360. PubMed ID: 27690261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of Focused Compound Library Targeting Liver X Receptors in Pancreatic Cancer Identified Ligands with Inverse Agonist and Degrader Activity.
    Karaboga H; Huang W; Srivastava S; Widmann S; Addanki S; Gamage KT; Mazhar Z; Ebalunode JO; Briggs JM; Gustafsson JÅ; Filgueira CS; Gilbertson SR; Lin CY
    ACS Chem Biol; 2020 Nov; 15(11):2916-2928. PubMed ID: 33074669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics.
    Li N; Wang X; Xu Y; Lin Y; Zhu N; Liu P; Lu D; Si S
    Mol Pharmacol; 2017 Apr; 91(4):264-276. PubMed ID: 28087808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?
    Wu G; Wang Q; Xu Y; Li J; Zhang H; Qi G; Xia Q
    Cell Death Dis; 2019 May; 10(6):416. PubMed ID: 31138790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholestenoic acid analogues as inverse agonists of the liver X receptors.
    Alvarez LD; Dansey MV; Ogara MF; Peña CI; Houtman R; Veleiro AS; Pecci A; Burton G
    J Steroid Biochem Mol Biol; 2020 May; 199():105585. PubMed ID: 31931135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of new LXR modulators that regulate LXR target genes and reduce lipogenesis in human cell models.
    Høgmoen Åstrand OA; Gikling I; Sylte I; Rustan AC; Thoresen GH; Rongved P; Kase ET
    Eur J Med Chem; 2014 Mar; 74():258-63. PubMed ID: 24480357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold.
    Goher SS; Griffett K; Hegazy L; Elagawany M; Arief MMH; Avdagic A; Banerjee S; Burris TP; Elgendy B
    Bioorg Med Chem Lett; 2019 Feb; 29(3):449-453. PubMed ID: 30587446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma.
    Na TY; Shin YK; Roh KJ; Kang SA; Hong I; Oh SJ; Seong JK; Park CK; Choi YL; Lee MO
    Hepatology; 2009 Apr; 49(4):1122-31. PubMed ID: 19105208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypolipogenic Effect of Shikimic Acid Via Inhibition of MID1IP1 and Phosphorylation of AMPK/ACC.
    Kim MJ; Sim DY; Lee HM; Lee HJ; Kim SH
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30700011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor.
    Kim GH; Oh GS; Yoon J; Lee GG; Lee KU; Kim SW
    J Clin Invest; 2015 Jan; 125(1):183-93. PubMed ID: 25437875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A liver-selective LXR inverse agonist that suppresses hepatic steatosis.
    Griffett K; Solt LA; El-Gendy Bel-D; Kamenecka TM; Burris TP
    ACS Chem Biol; 2013 Mar; 8(3):559-67. PubMed ID: 23237488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.
    Flaveny CA; Griffett K; El-Gendy Bel-D; Kazantzis M; Sengupta M; Amelio AL; Chatterjee A; Walker J; Solt LA; Kamenecka TM; Burris TP
    Cancer Cell; 2015 Jul; 28(1):42-56. PubMed ID: 26120082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors.
    Joseph SB; Laffitte BA; Patel PH; Watson MA; Matsukuma KE; Walczak R; Collins JL; Osborne TF; Tontonoz P
    J Biol Chem; 2002 Mar; 277(13):11019-25. PubMed ID: 11790787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying selective agonists targeting LXRβ from terpene compounds of alismatis rhizoma.
    Lin C; Li J; Wu C; Bao J
    J Mol Model; 2021 Feb; 27(3):91. PubMed ID: 33616795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystallography-guided discovery of carbazole-based retinoic acid-related orphan receptor gamma-t (RORγt) modulators: insights into different protein behaviors with "short" and "long" inverse agonists.
    Yu MC; Yang F; Ding XY; Sun NN; Jiang ZY; Huang YF; Yan YR; Zhu C; Xie Q; Chen ZF; Guo SQ; Jiang HL; Chen KX; Luo C; Luo XM; Chen SJ; Wang YH
    Acta Pharmacol Sin; 2021 Sep; 42(9):1524-1534. PubMed ID: 33239687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC5 Inhibits Hepatic Lipogenic Genes Expression by Attenuating the Transcriptional Activity of Liver X Receptor.
    Jia HY; Li QZ; Lv LF
    Cell Physiol Biochem; 2016; 39(4):1561-7. PubMed ID: 27614433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
    Han X; Cui ZY; Song J; Piao HQ; Lian LH; Hou LS; Wang G; Zheng S; Dong XX; Nan JX; Wu YL
    Chem Biol Interact; 2019 Sep; 311():108794. PubMed ID: 31421115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.